Detalles de la búsqueda
1.
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression.
Int J Neuropsychopharmacol
; 25(4): 269-279, 2022 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022754
2.
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Depress Anxiety
; 38(11): 1120-1130, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293233
3.
Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
Int J Neuropsychopharmacol
; 23(9): 549-558, 2020 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32367114
4.
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Int J Neuropsychopharmacol
; 22(10): 616-630, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31290965
5.
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
J Affect Disord
; 281: 767-775, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33261932
6.
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.
CNS Drugs
; 35(7): 781-794, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34235612
7.
Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Adv Pharmacol
; 89: 237-259, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32616208
8.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Focus (Am Psychiatr Publ)
; 17(1): 55-65, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32015715
9.
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
JAMA Psychiatry
; 75(2): 139-148, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282469
10.
Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study.
Psychopharmacology (Berl)
; 235(4): 1107-1119, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29392371
11.
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Am J Psychiatry
; 175(7): 620-630, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29656663
12.
The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.
Psychopharmacology (Berl)
; 234(21): 3175-3183, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28755104
13.
Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study.
Biol Psychiatry
; 80(6): 424-431, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26707087
14.
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
Am J Psychiatry
; 173(8): 816-26, 2016 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27056608
15.
Approval of esketamine for treatment-resistant depression.
Lancet Psychiatry
; 7(3): 232-235, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32087801
Resultados
1 -
15
de 15
1
Próxima >
>>